Chronic Lymphocytic Leukemia

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

David C. Fisher, MD, discusses the evolving role of BTK inhibitors in the CLL treatment paradigm.

Retreatment with venetoclax plus rituximab generated responses in patients with CLL who had responded to and progressed after initial venetoclax treatment.

Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.

A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.

Zanubrutinib was associated with lower treatment switching rates vs acalabrutinib and ibrutinib in real-world chronic lymphocytic leukemia.

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Alessandra Tedeschi, MD, discusses preliminary data from arm D of the SEQUOIA trial evaluating zanubrutinib plus venetoclax in high-risk, untreated CLL/SLL.

Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.

BGB-16673 has received FDA fast track designation for relapsed or refractory CLL or SLL following 2 or more prior lines of therapy.

Alexey Danilov, MD, PhD discusses unmet needs for patients with chronic lymphocytic leukemia.

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

Alessandra Tedeschi, MD, discusses the utility of zanubrutinib plus venetoclax in patients with CLL/SLL harboring deletion 17p and/or TP53 mutations.

Acalabrutinib-containing regimens demonstrated long-term efficacy with a tolerable safety profile in higher-risk chronic lymphocytic leukemia.

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Consuelo Bertossi, MD, discusses centralized academic reference diagnostics and biobanking in prospective, multicenter clinical trials.

Alessandra Tedeschi, MD, discusses 10-year follow-up data on treatment with first-line ibrutinib in treatment-naive chronic lymphocytic leukemia.

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.

An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.

Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia.

Stephen Opat, MBBS, discusses data for sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Pirtobrutinib generated responses in BTK inhibitor–naive relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Alexey Danilov, MD, PhD, discusses the importance of using BTK as a target, as well as recent updates on BTK degraders within the CLL treatment paradigm.

Medical experts deliberate on strategies for managing newly developed or exacerbated hypertension in patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia.

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

Alexey Danilov, MD, PhD, highlights the evolution of targeting BTK, sharing new data on BTK degraders and more in chronic lymphocytic leukemia

Minimal residual disease status was associated with progression-free survival in chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.